Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Bispecific antibody
CD3
CEACAM5
Immunotherapy
Solid cancer
T-cell engager
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
received:
19
10
2023
accepted:
25
11
2023
medline:
13
12
2023
pubmed:
13
12
2023
entrez:
13
12
2023
Statut:
epublish
Résumé
T-cell retargeting to eliminate CEACAM5-expressing cancer cells via CEACAM5xCD3 bispecific antibodies (BsAbs) showed limited clinical activity so far, mostly due to insufficient T-cell activation, dose-limiting toxicities, and formation of anti-drug antibodies (ADA). We present here the generation and preclinical development of NILK-2301, a BsAb composed of a common heavy chain and two different light chains, one kappa and one lambda, determining specificity (so-called κλ body format). NILK-2301 binds CD3ɛ on T-cells with its lambda light chain arm with an affinity of ≈100 nM, and the CEACAM5 A2 domain on tumor cells by its kappa light chain arm with an affinity of ≈5 nM. FcγR-binding is abrogated by the "LALAPA" mutation (Leu234Ala, Leu235Ala, Pro329Ala). NILK-2301 induced T-cell activation, proliferation, cytokine release, and T-cell dependent cellular cytotoxicity of CEACAM5-positive tumor cell lines (5/5 colorectal, 2/2 gastric, 2/2 lung), e.g., SK-CO-1 (E In summary, NILK-2301 combines promising preclinical activity and safety with lower probability of ADA-generation due to its format compared to other molecules and is scheduled to enter clinical testing at the end of 2023.
Sections du résumé
BACKGROUND
BACKGROUND
T-cell retargeting to eliminate CEACAM5-expressing cancer cells via CEACAM5xCD3 bispecific antibodies (BsAbs) showed limited clinical activity so far, mostly due to insufficient T-cell activation, dose-limiting toxicities, and formation of anti-drug antibodies (ADA).
METHODS
METHODS
We present here the generation and preclinical development of NILK-2301, a BsAb composed of a common heavy chain and two different light chains, one kappa and one lambda, determining specificity (so-called κλ body format).
RESULTS
RESULTS
NILK-2301 binds CD3ɛ on T-cells with its lambda light chain arm with an affinity of ≈100 nM, and the CEACAM5 A2 domain on tumor cells by its kappa light chain arm with an affinity of ≈5 nM. FcγR-binding is abrogated by the "LALAPA" mutation (Leu234Ala, Leu235Ala, Pro329Ala). NILK-2301 induced T-cell activation, proliferation, cytokine release, and T-cell dependent cellular cytotoxicity of CEACAM5-positive tumor cell lines (5/5 colorectal, 2/2 gastric, 2/2 lung), e.g., SK-CO-1 (E
CONCLUSIONS
CONCLUSIONS
In summary, NILK-2301 combines promising preclinical activity and safety with lower probability of ADA-generation due to its format compared to other molecules and is scheduled to enter clinical testing at the end of 2023.
Identifiants
pubmed: 38087365
doi: 10.1186/s13045-023-01516-3
pii: 10.1186/s13045-023-01516-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117Informations de copyright
© 2023. The Author(s).
Références
EMBO J. 1985 Feb;4(2):337-44
pubmed: 2410254
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Immunol Rev. 2017 Mar;276(1):145-164
pubmed: 28258703
J Exp Med. 1965 Mar 1;121:439-62
pubmed: 14270243
BMC Biol. 2010 Feb 04;8:12
pubmed: 20132533
Oncoimmunology. 2016 Jun 24;5(8):e1203498
pubmed: 27622073
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Mol Biol Rep. 2012 Apr;39(4):3695-704
pubmed: 21725636
Biomedicines. 2022 Mar 11;10(3):
pubmed: 35327456
Int Rev Immunol. 1997;16(1-2):57-85
pubmed: 9651786
MAbs. 2016 Aug-Sep;8(6):1064-78
pubmed: 27232760
Nat Rev Immunol. 2023 Jul 4;:
pubmed: 37402992
Clin Cancer Res. 2020 Dec 15;26(24):6589-6599
pubmed: 33046521
Cells. 2022 Oct 06;11(19):
pubmed: 36231109
J Clin Oncol. 2017 Oct 10;35(29):3338-3346
pubmed: 28817371
J Clin Oncol. 2023 Feb 20;41(6):1265-1274
pubmed: 35658469
Ann Oncol. 2022 Apr;33(4):416-425
pubmed: 35026412
J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):231-239
pubmed: 23280407
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Cancer Metastasis Rev. 2013 Dec;32(3-4):643-71
pubmed: 23903773
Eur J Immunol. 2021 Aug;51(8):2074-2085
pubmed: 33945643
Lancet. 2021 Aug 21;398(10301):665-674
pubmed: 34388396
Front Immunol. 2023 May 15;14:1188049
pubmed: 37256141
Cancer Lett. 2006 Mar 28;234(2):158-67
pubmed: 15893415
Cancer Res. 1989 Feb 15;49(4):847-52
pubmed: 2912558
Oncoimmunology. 2021 Aug 18;10(1):1960729
pubmed: 34434611
Clin Cancer Res. 2016 Jul 1;22(13):3286-97
pubmed: 26861458
Nat Commun. 2015 Feb 12;6:6113
pubmed: 25672245
Exp Hematol Oncol. 2023 Jan 16;12(1):10
pubmed: 36647169
Clin Colorectal Cancer. 2016 Dec;15(4):345-351
pubmed: 27591895
J Biol Chem. 2001 Mar 2;276(9):6591-604
pubmed: 11096108
Nat Rev Cancer. 2015 Jun;15(6):361-70
pubmed: 25998715
Biochem Biophys Res Commun. 2005 Jul 22;333(1):223-9
pubmed: 15958210
N Engl J Med. 2022 Feb 17;386(7):640-654
pubmed: 34891224
Curr Opin Cell Biol. 2006 Oct;18(5):565-71
pubmed: 16919437
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Clin Colorectal Cancer. 2018 Jun;17(2):e189-e199
pubmed: 29233603
J Clin Invest. 1988 Aug;82(2):586-93
pubmed: 3042807
J Immunother. 2016 Sep;39(7):279-89
pubmed: 27404941
J Hematol Oncol. 2021 May 3;14(1):75
pubmed: 33941237
Sci Transl Med. 2019 Jun 12;11(496):
pubmed: 31189721
MAbs. 2019 Feb/Mar;11(2):322-334
pubmed: 30569825
J Hematol Oncol. 2023 Jul 27;16(1):83
pubmed: 37501154
Semin Cancer Biol. 1999 Apr;9(2):67-81
pubmed: 10202129
Sci Transl Med. 2020 Jan 8;12(525):
pubmed: 31915305
J Clin Oncol. 2005 Sep 20;23(27):6763-70
pubmed: 16170184
MAbs. 2014;6(6):1571-84
pubmed: 25484061
Mol Immunol. 1992 Jan;29(1):53-9
pubmed: 1530984
Cancer Cell. 2017 Mar 13;31(3):396-410
pubmed: 28262554
J Clin Oncol. 2021 Jun 20;39(18):1959-1970
pubmed: 33739857
J Exp Med. 1965 Sep 1;122(3):467-81
pubmed: 4953873